Midatech Pharma plc – LSE:MTPH.L

Midatech Pharma stock price today

GBP 18.25
+0.25
+1.39%

Midatech Pharma stock price monthly change

+1046.50%
month

Midatech Pharma stock price quarterly change

+700.00%
quarter

Midatech Pharma stock price yearly change

+41.18%
year

Midatech Pharma key metrics

Market Cap
 31.20M
Enterprise value
 N/A
P/E
 N/A
EV/Sales
 N/A
EV/EBITDA
 N/A
Price/Sales
 N/A
Price/Book
 N/A
PEG ratio
 N/A
EPS
 N/A
Revenue
 N/A
EBITDA
 N/A
Income
 N/A
Revenue Q/Q
 N/A
Revenue Y/Y
 N/A
Profit margin
 0%
Oper. margin
 0%
Gross margin
 0%
EBIT margin
 0%
EBITDA margin
 N/A

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Midatech Pharma stock price history

Midatech Pharma stock forecast

Midatech Pharma financial statements

Profit Margin

Midatech Pharma plc (LSE:MTPH.L): Profit margin
Jun 2018 0 0
MTPH.L income statement history

Debt to Assets

Midatech Pharma plc (LSE:MTPH.L): Debt to assets
Jun 2021 8275000 4.52M 54.65%
Dec 2021 12913000 2.46M 19.05%
Jun 2022 9682000 2.19M 22.62%
Dec 2022 5525000 2.36M 42.77%
MTPH.L balance sheet history

Cash Flow

Midatech Pharma plc (LSE:MTPH.L): Cash Flow
Jun 2018 -3.36M -54.75K -1.45M
Jan 2019 -1.62M -953.75K 3.66M
Mar 2019 -1.62M -953.75K 3.66M
Jun 2019 -1.62M -953.75K 3.66M
MTPH.L cash flow history

Midatech Pharma alternative data

Midatech Pharma
Employees

Midatech Pharma plc (LSE:MTPH.L): Employee count
Aug 2023 20
Sep 2023 20
Oct 2023 20
Nov 2023 20
Dec 2023 20
Jan 2024 20
Feb 2024 20
Mar 2024 20
Apr 2024 20
May 2024 20
Jun 2024 20
Jul 2024 20

Midatech Pharma other data

Frequently Asked Questions (FAQ)

  • What's the price of Midatech Pharma stock today?

    One share of Midatech Pharma stock can currently be purchased for approximately $18.25.

  • When is Midatech Pharma's next earnings date?

    Unfortunately, Midatech Pharma's (MTPH.L) next earnings date is currently unknown.

  • Does Midatech Pharma pay dividends?

    No, Midatech Pharma does not pay dividends.

  • How much money does Midatech Pharma make?

    Midatech Pharma has a market capitalization of 31.20M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 20.93% to 699K US dollars.

  • What is Midatech Pharma's stock symbol?

    Midatech Pharma plc is traded on the LSE under the ticker symbol "MTPH.L".

  • What is Midatech Pharma's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Midatech Pharma?

    Shares of Midatech Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Midatech Pharma's key executives?

    Midatech Pharma's management team includes the following people:

    • Mr. Stephen A. Stamp Chief Executive Officer, Chief Financial Officer, Company Sec. & Director(age: 63, pay: $193,170)

  • How many employees does Midatech Pharma have?

    As Jul 2024, Midatech Pharma employs 20 workers.

  • When Midatech Pharma went public?

    Midatech Pharma plc is publicly traded company for more then 10 years since IPO on 8 Dec 2014.

  • What is Midatech Pharma's official website?

    The official website for Midatech Pharma is midatechpharma.com.

  • How can i contact Midatech Pharma?

    Midatech Pharma can be reached via phone at +44 29 2048 0180.

Midatech Pharma company profile:

Midatech Pharma plc

midatechpharma.com
Exchange:

LSE

Full time employees:

20

Industry:

Biotechnology

Sector:

Healthcare

Midatech Pharma plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

+44 29 2048 0180
1 Caspian Point
Cardiff, CF10 4DQ

:
ISIN: GB00BKT14T00
CUSIP: G6091U194